
Delineate turns scientific publications, patents, and databases into actionable, structured datasets so biopharma teams can quickly answer research questions. The company uses AI and NLP to locate relevant literature, extract data from text, tables, figures and plots, and normalize results into fit-for-purpose datasets. It offers bespoke AI services and data pipelines that support analysis workflows common in drug discovery and R&D, positioning it as a B2B data/AI provider for life sciences. Delineate’s tooling accelerates evidence synthesis and enables rapid downstream analysis and decision support for biopharma organizations.

Delineate turns scientific publications, patents, and databases into actionable, structured datasets so biopharma teams can quickly answer research questions. The company uses AI and NLP to locate relevant literature, extract data from text, tables, figures and plots, and normalize results into fit-for-purpose datasets. It offers bespoke AI services and data pipelines that support analysis workflows common in drug discovery and R&D, positioning it as a B2B data/AI provider for life sciences. Delineate’s tooling accelerates evidence synthesis and enables rapid downstream analysis and decision support for biopharma organizations.
What they do: Convert scientific publications, patents, and databases into structured, actionable datasets for biopharma using AI/NLP
Founded: 2024
Headquarters: Boston, Massachusetts, USA
Recent funding: Pre-Seed announced Mar 12, 2025; reported $500K
Investors: Y Combinator; Unpopular Ventures
Evidence synthesis and data extraction for biopharma research and R&D
2024
Biotechnology
500000 USD
Investors listed include Y Combinator and Unpopular Ventures
“Y Combinator participation”